What the superinvestors bought and sold in 2026 Q2
2026 Q2
136 of 137 filedThe quarter at a glance
74 of 133 managers were net sellers. Setting price aside, they put $9.9B to work, led by Communication Services (+$15.7B), while trimming Information Technology (−$5B). TMO was the most widely bought stock (13 bought, 4 sold); GOOGL / GOOG the most widely sold (36 sold, 22 bought).
Net buyers
54 of 133 managers
74 sold more than they bought · 5 about even
Net bought
+$9.9B
Price moves taken out; prices alone moved the book +$158.2B.
Positions opened
856
951 closed out. IPOs, spin-offs and mergers left out.
Combined book, last quarter
+14.5%
SPY +14.8%,
0.4 pts behind.
Price only.
Most bought and sold
Ranked by how many managers bought minus how many sold, with price moves taken out. Open a stock to see who.
Most bought
-
1 TMO Thermo Fisher Scientific, Inc. 13 bought · 4 sold +$1.7B
Bought by
- Glenview Capital Management added 3.1% → 5.7%
- Andreas Halvorsen - Viking Global Investors added 2.3% → 2.8%
- Harry Burn - Sound Shore Management opened 2.6% of book
- Farallon Capital Management added 2.5% → 2.4%
- Senator Investment Group opened 1.8% of book
- First Pacific Advisors added 1.5% → 1.5%
- Dan Sundheim - D1 Capital Partners added 3.2% → 1.2%
- David Katz - Matrix Asset Advisors added 1.0% → 1.1%
and 5 more
Sold by
- Lindsell Train cut 9.7% → 9.8%
- William Von Mueffling - Cantillon Capital Management closed was 2.5%
- Murphy Pohlad - Murphy Pohlad Asset Management cut 0.45% → 0.41%
- Ron Baron - Bamco Inc. (Baron Capital) cut 0.04% → <0.01%
-
2 VUG Vanguard Index Fds 9 bought · 0 sold +$8M
Bought by
- Murphy Pohlad - Murphy Pohlad Asset Management added 0.20% → 0.22%
- David Katz - Matrix Asset Advisors added 0.13% → 0.13%
- Polen Capital Management added 0.05% → 0.05%
- Torray Investment Partners added 0.12% → 0.05%
- Kentucky Trust Co. - Kentucky Trust added 0.01% → 0.01%
- Mairs & Power added <0.01% → <0.01%
- Arnold Van Den Berg - Van Den Berg Management I added <0.01% → <0.01%
- Cathie Wood - Ark Investment Management added <0.01% → <0.01%
and 1 more
Sold by
No manager sold.
-
3 MU Micron Technology Inc. 11 bought · 4 sold +$9.1B
Bought by
- Situational Awareness added 0.04% → 27.5%
- Philippe Laffont - Coatue Management added 0.19% → 7.5%
- Nehal Chopra - Ratan Capital Management opened 4.8% of book
- Brad Gerstner - Altimeter Capital Management opened 2.5% of book
- Ben Hoskin - Value Aligned Research Advisors added 0.36% → 2.1%
- Davidson Kempner Capital Management added 0.20% → 0.75%
- Spencer Waxman - Shannon River Fund Management opened 0.46% of book
- George Soros - Soros Fund Management added 0.01% → 0.32%
and 3 more
Sold by
- David Tepper - Appaloosa cut 9.5% → 14.6%
- Gavin Baker - Atreides Management cut 5.1% → 5.7%
- Stanley Druckenmiller - Duquesne Family Office closed was 0.23%
- Mairs & Power cut <0.01% → <0.01%
-
4 DHR Danaher Corp. Del 9 bought · 2 sold +$390M
Bought by
- Ben Jacobs - Anomaly Capital Management added 8.8% → 9.9%
- Pat Dorsey - Dorsey Asset Management added 8.8% → 7.6%
- Glenview Capital Management added 0.74% → 4.0%
- Arnold Van Den Berg - Van Den Berg Management I added 1.6% → 1.7%
- First Pacific Advisors opened 1.3% of book
- Chase Coleman - Tiger Global Management opened 0.36% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.18% of book
- Dodge & Cox added <0.01% → 0.03%
and 1 more
Sold by
- Senator Investment Group cut 3.8% → 2.4%
- Lee Ainslie - Maverick Capital closed was 1.8%
-
5 DVN Devon Energy Corp. 6 bought · 0 sold +$1.1B
Bought by
- Christopher Davis - Davis Selected Advisers opened 4.5% of book
- John Armitage - Egerton Capital (UK) added 3.6% → 3.0%
- Arnold Van Den Berg - Van Den Berg Management I added 0.33% → 0.55%
- Don Yacktman - Yacktman Asset Management added 0.31% → 0.26%
- Tweedy, Browne Co. added 0.10% → 0.11%
- Kentucky Trust Co. - Kentucky Trust added <0.01% → <0.01%
Sold by
No manager sold.
-
6 STM Stmicroelectronics 6 bought · 0 sold +$830M
Bought by
- Stanley Druckenmiller - Duquesne Family Office added 2.7% → 4.5%
- Sachem Head Capital Management opened 3.4% of book
- Situational Awareness opened 2.9% of book
- Glenview Capital Management opened 0.76% of book
- George Soros - Soros Fund Management opened 0.02% of book
- Lee Ainslie - Maverick Capital opened <0.01% of book
Sold by
No manager sold.
-
7 ADBE Adobe, Inc. 8 bought · 2 sold +$50M
Bought by
- Hillman Capital Management added 2.7% → 2.6%
- Samantha Mclemore - Patient Capital Management added 2.6% → 2.4%
- Bill Nygren / Oakmark - Harris Associates L P added 0.74% → 0.77%
- Dodge & Cox added 0.33% → 0.33%
- Murphy Pohlad - Murphy Pohlad Asset Management opened 0.18% of book
- Christopher Davis - Davis Selected Advisers added 0.05% → 0.06%
- George Soros - Soros Fund Management opened 0.06% of book
- Richard Pzena - Pzena Investment Management added <0.01% → <0.01%
Sold by
- William Von Mueffling - Cantillon Capital Management closed was 1.6%
- Polen Capital Management cut 0.02% → 0.01%
-
8 SNOW Snowflake Inc. 9 bought · 4 sold +$707M
Bought by
- Ram Parameswaran - Octahedron Capital Management added 3.7% → 5.5%
- Lee Ainslie - Maverick Capital opened 2.2% of book
- Glen Kacher - Light Street Capital Management opened 2.0% of book
- Alex Sacerdote - Whale Rock Capital Management opened 1.8% of book
- Andreas Halvorsen - Viking Global Investors opened 0.70% of book
- Cathie Wood - Ark Investment Management opened 0.45% of book
- George Soros - Soros Fund Management added 0.08% → 0.43%
- Davidson Kempner Capital Management added 0.19% → 0.30%
and 1 more
Sold by
- Spencer Waxman - Shannon River Fund Management closed was 0.76%
- Gavin Baker - Atreides Management closed was 0.44%
- Ben Hoskin - Value Aligned Research Advisors closed was 0.35%
- Ron Baron - Bamco Inc. (Baron Capital) cut 0.18% → 0.13%
-
9 SHAZ Sharonai Holdings Inc. 5 bought · 0 sold +$527M
Bought by
- Situational Awareness added 0.13% → 2.3%
- Stephen Mandel - Lone Pine Capital opened 0.63% of book
- Howard Marks - Oaktree Capital Management opened 0.34% of book
- George Soros - Soros Fund Management opened 0.08% of book
- Davidson Kempner Capital Management opened 0.05% of book
Sold by
No manager sold.
-
10 GEV Ge Vernova Inc. 7 bought · 2 sold +$522M
Bought by
- Terry Smith - Fundsmith opened 3.5% of book
- Polen Capital Management opened 2.0% of book
- Ben Jacobs - Anomaly Capital Management opened 1.5% of book
- Arnold Van Den Berg - Van Den Berg Management I opened 0.05% of book
- Lee Ainslie - Maverick Capital opened 0.01% of book
- Richard Pzena - Pzena Investment Management opened <0.01% of book
- Ron Baron - Bamco Inc. (Baron Capital) opened <0.01% of book
Sold by
- Chase Coleman - Tiger Global Management cut 3.7% → 3.9%
- Kentucky Trust Co. - Kentucky Trust cut 0.24% → 0.27%
Not counted as buying: 182 IPOs, spin-offs and new listings.
Most sold
-
1 GOOGL / GOOG Alphabet 22 bought · 36 sold +$11.6B
Sold by
- Lindsell Train cut 15.6% → 17.5%
- Ruane, Cunniff & Goldfarb cut 14.6% → 16.2%
- Mala Gaonkar - Surgocap Partners cut 14.3% → 11.0%
- Chase Coleman - Tiger Global Management cut 13.4% → 8.7%
- First Pacific Advisors cut 12.1% → 12.0%
- David Abrams - Abrams Capital Management cut 11.6% → 8.9%
- Thomas Russo - Gardner Russo & Quinn cut 11.4% → 12.1%
- John Armitage - Egerton Capital (UK) cut 11.0% → 11.2%
and 28 more
Bought by
- Andrew Steginsky - Steginsky Capital added 33.1% → 37.3%
- Warren Buffett - Berkshire Hathaway added 6.3% → 12.6%
- Ben Jacobs - Anomaly Capital Management added 4.5% → 12.3%
- Grant Wonders - Voyager Global Management added 4.9% → 11.1%
- Dan Loeb - Third Point added 2.4% → 9.5%
- Seth Klarman - Baupost Group added 6.6% → 9.0%
- David Tepper - Appaloosa added 8.4% → 8.5%
- Chris Hohn - Tci Fund Management added 7.2% → 8.3%
and 14 more
-
2 NVDA Nvidia Corporation 7 bought · 20 sold −$116M
Sold by
- Marc Stad - Dragoneer Investment Group closed was 21.7%
- Duan Yongping - H&H International Investment cut 12.1% → 6.6%
- Nehal Chopra - Ratan Capital Management closed was 11.3%
- Chase Coleman - Tiger Global Management cut 9.2% → 9.3%
- Glen Kacher - Light Street Capital Management cut 8.9% → 3.0%
- Mala Gaonkar - Surgocap Partners closed was 5.9%
- Ning Jin - Avantyr Capital Partners cut 5.8% → 4.1%
- Jensen Investment Management cut 5.6% → 5.8%
and 12 more
Bought by
- Grant Wonders - Voyager Global Management added 27.9% → 28.1%
- John Armitage - Egerton Capital (UK) added 5.2% → 6.6%
- Lewis Sanders - Sanders Capital added 1.5% → 4.5%
- Cathie Wood - Ark Investment Management added 1.4% → 1.8%
- Christopher Davis - Davis Selected Advisers added 0.09% → 0.13%
- Steven Check - Check Capital Management added 0.01% → 0.02%
- Richard Pzena - Pzena Investment Management opened <0.01% of book
-
3 AVGO Broadcom Inc. 7 bought · 16 sold −$1.2B
Sold by
- William Von Mueffling - Cantillon Capital Management cut 8.3% → 10.6%
- Polen Capital Management cut 5.8% → 6.4%
- Estuary Capital Management closed was 5.5%
- Chase Coleman - Tiger Global Management cut 4.9% → 2.8%
- Nehal Chopra - Ratan Capital Management closed was 4.8%
- Farallon Capital Management cut 3.1% → 2.0%
- Alex Sacerdote - Whale Rock Capital Management cut 2.9% → 0.18%
- Jensen Investment Management cut 2.7% → 3.6%
and 8 more
Bought by
- Philippe Laffont - Coatue Management added 5.9% → 4.5%
- Lewis Sanders - Sanders Capital opened 2.0% of book
- Ryan Packard - Hiddenite Capital Partners opened 1.5% of book
- George Soros - Soros Fund Management added 0.53% → 0.77%
- David Tepper - Appaloosa opened 0.73% of book
- Ben Hoskin - Value Aligned Research Advisors added 0.07% → 0.38%
- Lee Ainslie - Maverick Capital opened 0.02% of book
-
4 TSM Taiwan Semiconductor Manufac 12 bought · 20 sold −$1.2B
Sold by
- Grant Wonders - Voyager Global Management cut 13.2% → 12.8%
- Mala Gaonkar - Surgocap Partners cut 12.5% → 14.0%
- Lewis Sanders - Sanders Capital cut 11.3% → 12.5%
- Philippe Laffont - Coatue Management cut 10.8% → 8.8%
- David Rolfe - Wedgewood Partners cut 9.0% → 10.4%
- Chase Coleman - Tiger Global Management cut 8.2% → 9.7%
- Ruane, Cunniff & Goldfarb cut 6.8% → 8.7%
- William Von Mueffling - Cantillon Capital Management cut 5.6% → 8.2%
and 12 more
Bought by
- David Tepper - Appaloosa added 7.6% → 10.2%
- Brad Gerstner - Altimeter Capital Management added 8.1% → 6.9%
- Situational Awareness added 0.06% → 6.2%
- Stanley Druckenmiller - Duquesne Family Office added 5.0% → 5.4%
- Dan Loeb - Third Point added 4.5% → 4.7%
- Terry Smith - Fundsmith opened 4.0% of book
- Eric Mandelblatt - Soroban Capital Partners added 1.3% → 2.2%
- Polen Capital Management added 0.41% → 2.1%
and 4 more
-
5 LITE Lumentum Hldgs Inc. 1 bought · 9 sold −$689M
Sold by
- Estuary Capital Management closed was 6.2%
- Gavin Baker - Atreides Management closed was 3.8%
- Ben Hoskin - Value Aligned Research Advisors cut 3.6% → 1.6%
- Ram Parameswaran - Octahedron Capital Management closed was 2.8%
- Nehal Chopra - Ratan Capital Management closed was 1.8%
- Chase Coleman - Tiger Global Management closed was 0.42%
- Glen Kacher - Light Street Capital Management closed was 0.38%
- Stanley Druckenmiller - Duquesne Family Office closed was 0.14%
and 1 more
Bought by
- Polen Capital Management opened <0.01% of book
-
6 WST West Pharmaceutical Svsc Inc. 0 bought · 8 sold −$173M
Sold by
- Hillman Capital Management cut 1.6% → 1.8%
- Bill Miller - Miller Value Partners cut 1.0% → 0.81%
- Andreas Halvorsen - Viking Global Investors closed was 0.29%
- Ron Baron - Bamco Inc. (Baron Capital) cut 0.15% → 0.09%
- Stanley Druckenmiller - Duquesne Family Office closed was 0.07%
- Lee Ainslie - Maverick Capital closed was 0.03%
- Farallon Capital Management closed was 0.03%
- First Eagle Investment Management cut <0.01% → <0.01%
Bought by
No manager bought.
-
7 TXN Texas Instruments, Inc. 4 bought · 11 sold −$1.9B
Sold by
- Terry Smith - Fundsmith cut 4.0% → 3.9%
- Torray Investment Partners cut 3.5% → 2.6%
- Dan Sundheim - D1 Capital Partners cut 3.0% → 0.35%
- Christopher Davis - Davis Selected Advisers cut 2.5% → 3.1%
- David Katz - Matrix Asset Advisors cut 2.5% → 2.4%
- Wallace Weitz - Weitz Investment Management cut 2.2% → 1.6%
- First Eagle Investment Management cut 0.94% → 0.03%
- Sarah Ketterer - Causeway Capital Management cut 0.49% → 0.54%
and 3 more
Bought by
- George Soros - Soros Fund Management opened 0.02% of book
- Lee Ainslie - Maverick Capital opened 0.01% of book
- Glenn Greenberg - Brave Warrior Advisors opened <0.01% of book
- Ron Baron - Bamco Inc. (Baron Capital) opened <0.01% of book
-
8 CRS Carpenter Technology Corp. 0 bought · 7 sold −$1.7B
Sold by
- Mala Gaonkar - Surgocap Partners cut 15.8% → 13.7%
- Dan Loeb - Third Point cut 5.9% → 2.8%
- John Armitage - Egerton Capital (UK) closed was 5.8%
- Stephen Mandel - Lone Pine Capital cut 5.7% → 3.6%
- George Soros - Soros Fund Management cut 0.04% → 0.03%
- Polen Capital Management cut 0.03% → 0.04%
- Cathie Wood - Ark Investment Management cut <0.01% → <0.01%
Bought by
No manager bought.
-
9 ADI Analog Devices Inc. 2 bought · 9 sold −$1.1B
Sold by
- First Pacific Advisors cut 7.7% → 7.8%
- Ako Capital cut 6.4% → 5.7%
- William Von Mueffling - Cantillon Capital Management cut 4.0% → 5.3%
- Wallace Weitz - Weitz Investment Management cut 2.4% → 2.3%
- Francois Rochon - Giverny Capital cut 2.0% → 1.2%
- Dan Sundheim - D1 Capital Partners cut 0.83% → 0.12%
- Sarah Ketterer - Causeway Capital Management cut 0.79% → 0.61%
- Mairs & Power cut <0.01% → <0.01%
and 1 more
Bought by
- Lee Ainslie - Maverick Capital opened <0.01% of book
- Glenn Greenberg - Brave Warrior Advisors opened <0.01% of book
-
10 SPY State Str Spdr S&P 500 ETF T 3 bought · 10 sold −$753M
Sold by
- Bill Miller - Miller Value Partners closed was 5.1%
- Lewis Sanders - Sanders Capital cut 2.3% → 1.5%
- Chris James - Meritage Group closed was 1.3%
- Mairs & Power cut 0.18% → 0.06%
- Francois Rochon - Giverny Capital cut 0.06% → 0.06%
- Davidson Kempner Capital Management cut 0.05% → 0.04%
- Don Yacktman - Yacktman Asset Management cut 0.03% → 0.03%
- First Eagle Investment Management closed was 0.01%
and 2 more
Bought by
- Senator Investment Group added 0.09% → 0.18%
- Kentucky Trust Co. - Kentucky Trust added 0.07% → 0.08%
- Polen Capital Management added 0.02% → 0.03%
Not counted as selling: 160 mergers and delistings.
Opened and closed
New positions started from zero, and positions sold down to zero. IPOs, spin-offs and mergers are left out.
Opened by the most managers
-
AMD Advanced Micro Devices Inc. 9 managers avg 3.1% of book · Marc Stad - Dragoneer Investment Group, Spencer Waxman - Shannon River Fund Management and 7 more
Opened by
- Marc Stad - Dragoneer Investment Group opened 19.3% of book
- Spencer Waxman - Shannon River Fund Management opened 5.5% of book
- Chase Coleman - Tiger Global Management opened 1.6% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.81% of book
- Ben Hoskin - Value Aligned Research Advisors opened 0.23% of book
- Philippe Laffont - Coatue Management opened 0.11% of book
- Ron Baron - Bamco Inc. (Baron Capital) opened 0.01% of book
- Polen Capital Management opened <0.01% of book
and 1 more
-
META Meta Platforms Inc. 8 managers avg 3.3% of book · Bill Ackman - Pershing Square, Chris James - Meritage Group and 6 more
Opened by
- Bill Ackman - Pershing Square opened 9.2% of book
- Chris James - Meritage Group opened 6.2% of book
- Clifford Sosin - Cas Investment Partners opened 4.1% of book
- Lee Ainslie - Maverick Capital opened 3.8% of book
- Gavin Baker - Atreides Management opened 1.6% of book
- Dan Sundheim - D1 Capital Partners opened 0.92% of book
- Bill Miller - Miller Value Partners opened 0.85% of book
- Ben Hoskin - Value Aligned Research Advisors opened <0.01% of book
-
STX Seagate Technology Hldngs Pl 8 managers avg 2.5% of book · Sachem Head Capital Management, Stephen Mandel - Lone Pine Capital and 6 more
Opened by
- Sachem Head Capital Management opened 9.5% of book
- Stephen Mandel - Lone Pine Capital opened 5.9% of book
- Nehal Chopra - Ratan Capital Management opened 1.2% of book
- Alex Sacerdote - Whale Rock Capital Management opened 1.2% of book
- Chase Coleman - Tiger Global Management opened 1.1% of book
- Ryan Packard - Hiddenite Capital Partners opened 0.83% of book
- Dan Sundheim - D1 Capital Partners opened 0.08% of book
- Lee Ainslie - Maverick Capital opened 0.01% of book
-
GEV Ge Vernova Inc. 7 managers avg 1.0% of book · Terry Smith - Fundsmith, Polen Capital Management and 5 more
Opened by
- Terry Smith - Fundsmith opened 3.5% of book
- Polen Capital Management opened 2.0% of book
- Ben Jacobs - Anomaly Capital Management opened 1.5% of book
- Arnold Van Den Berg - Van Den Berg Management I opened 0.05% of book
- Lee Ainslie - Maverick Capital opened 0.01% of book
- Richard Pzena - Pzena Investment Management opened <0.01% of book
- Ron Baron - Bamco Inc. (Baron Capital) opened <0.01% of book
-
INTC Intel Corp. 6 managers avg 2.0% of book · Mala Gaonkar - Surgocap Partners, Philippe Laffont - Coatue Management and 4 more
Opened by
- Mala Gaonkar - Surgocap Partners opened 8.3% of book
- Philippe Laffont - Coatue Management opened 3.5% of book
- Alex Sacerdote - Whale Rock Capital Management opened 0.29% of book
- George Soros - Soros Fund Management opened 0.17% of book
- Tweedy, Browne Co. opened 0.02% of book
- Bill Nygren / Oakmark - Harris Associates L P opened <0.01% of book
-
SNOW Snowflake Inc. 6 managers avg 1.2% of book · Lee Ainslie - Maverick Capital, Glen Kacher - Light Street Capital Management and 4 more
Opened by
- Lee Ainslie - Maverick Capital opened 2.2% of book
- Glen Kacher - Light Street Capital Management opened 2.0% of book
- Alex Sacerdote - Whale Rock Capital Management opened 1.8% of book
- Andreas Halvorsen - Viking Global Investors opened 0.70% of book
- Cathie Wood - Ark Investment Management opened 0.45% of book
- Dan Sundheim - D1 Capital Partners opened 0.16% of book
-
LRCX Lam Research Corp. 6 managers avg 0.35% of book · Brad Gerstner - Altimeter Capital Management, Stanley Druckenmiller - Duquesne Family Office and 4 more
Opened by
- Brad Gerstner - Altimeter Capital Management opened 1.7% of book
- Stanley Druckenmiller - Duquesne Family Office opened 0.36% of book
- Lee Ainslie - Maverick Capital opened 0.02% of book
- Steven Check - Check Capital Management opened <0.01% of book
- Sarah Ketterer - Causeway Capital Management opened <0.01% of book
- Mairs & Power opened <0.01% of book
-
MSFT Microsoft Corp. 5 managers avg 4.9% of book · Bill Ackman - Pershing Square, Dennis Hong - Shawspring Partners and 3 more
Opened by
- Bill Ackman - Pershing Square opened 11.9% of book
- Dennis Hong - Shawspring Partners opened 7.3% of book
- Ram Parameswaran - Octahedron Capital Management opened 4.8% of book
- Rule One Partners opened 0.29% of book
- Christopher Bloomstran - Semper Augustus Investments Group opened 0.03% of book
-
SPGI S&P Global Inc. 5 managers avg 2.6% of book · Bill Ackman - Pershing Square, Triple Frond Partners and 3 more
Opened by
- Bill Ackman - Pershing Square opened 5.4% of book
- Triple Frond Partners opened 4.2% of book
- Christopher Bloomstran - Semper Augustus Investments Group opened 2.1% of book
- John Armitage - Egerton Capital (UK) opened 1.4% of book
- Glenn Greenberg - Brave Warrior Advisors opened 0.01% of book
-
MU Micron Technology Inc. 5 managers avg 1.6% of book · Nehal Chopra - Ratan Capital Management, Brad Gerstner - Altimeter Capital Management and 3 more
Opened by
- Nehal Chopra - Ratan Capital Management opened 4.8% of book
- Brad Gerstner - Altimeter Capital Management opened 2.5% of book
- Spencer Waxman - Shannon River Fund Management opened 0.46% of book
- Lee Ainslie - Maverick Capital opened 0.02% of book
- Bill Nygren / Oakmark - Harris Associates L P opened <0.01% of book
Closed out by the most managers
-
NVDA Nvidia Corporation 10 managers was avg 5.6% of book · Marc Stad - Dragoneer Investment Group, Nehal Chopra - Ratan Capital Management and 8 more
Closed by
- Marc Stad - Dragoneer Investment Group closed was 21.7%
- Nehal Chopra - Ratan Capital Management closed was 11.3%
- Mala Gaonkar - Surgocap Partners closed was 5.9%
- Estuary Capital Management closed was 5.5%
- Ram Parameswaran - Octahedron Capital Management closed was 5.5%
- Dan Sundheim - D1 Capital Partners closed was 2.4%
- Ryan Packard - Hiddenite Capital Partners closed was 2.3%
- Dan Loeb - Third Point closed was 1.6%
and 2 more
-
AVGO Broadcom Inc. 8 managers was avg 2.0% of book · Estuary Capital Management, Nehal Chopra - Ratan Capital Management and 6 more
Closed by
- Estuary Capital Management closed was 5.5%
- Nehal Chopra - Ratan Capital Management closed was 4.8%
- Dan Sundheim - D1 Capital Partners closed was 2.7%
- Stanley Druckenmiller - Duquesne Family Office closed was 1.8%
- Dan Loeb - Third Point closed was 0.74%
- Brad Gerstner - Altimeter Capital Management closed was 0.36%
- Davidson Kempner Capital Management closed was 0.21%
- Murphy Pohlad - Murphy Pohlad Asset Management closed was 0.11%
-
LITE Lumentum Hldgs Inc. 7 managers was avg 2.2% of book · Estuary Capital Management, Gavin Baker - Atreides Management and 5 more
Closed by
- Estuary Capital Management closed was 6.2%
- Gavin Baker - Atreides Management closed was 3.8%
- Ram Parameswaran - Octahedron Capital Management closed was 2.8%
- Nehal Chopra - Ratan Capital Management closed was 1.8%
- Chase Coleman - Tiger Global Management closed was 0.42%
- Glen Kacher - Light Street Capital Management closed was 0.38%
- Stanley Druckenmiller - Duquesne Family Office closed was 0.14%
-
INTU Intuit 6 managers was avg 1.2% of book · Dennis Hong - Shawspring Partners, Davidson Kempner Capital Management and 4 more
Closed by
- Dennis Hong - Shawspring Partners closed was 6.6%
- Davidson Kempner Capital Management closed was 0.34%
- Polen Capital Management closed was 0.06%
- Lee Ainslie - Maverick Capital closed was <0.01%
- Kentucky Trust Co. - Kentucky Trust closed was <0.01%
- Richard Pzena - Pzena Investment Management closed was <0.01%
-
MSFT Microsoft Corp. 6 managers was avg 0.96% of book · Chris Hohn - Tci Fund Management, Senator Investment Group and 4 more
Closed by
- Chris Hohn - Tci Fund Management closed was 2.2%
- Senator Investment Group closed was 2.0%
- David Tepper - Appaloosa closed was 0.56%
- Davidson Kempner Capital Management closed was 0.42%
- John Rogers - Ariel Investments closed was 0.26%
- Alex Sacerdote - Whale Rock Capital Management closed was 0.26%
-
RBLX Roblox Corp. 5 managers was avg 0.91% of book · Alex Sacerdote - Whale Rock Capital Management, Gavin Baker - Atreides Management and 3 more
Closed by
- Alex Sacerdote - Whale Rock Capital Management closed was 2.6%
- Gavin Baker - Atreides Management closed was 1.6%
- Henry Ellenbogen - Durable Capital Partners closed was 0.38%
- Davidson Kempner Capital Management closed was 0.04%
- Lee Ainslie - Maverick Capital closed was <0.01%
-
DIS Disney Walt Co. 5 managers was avg 0.46% of book · Farallon Capital Management, Valueact Capital - Valueact Holdings and 3 more
Closed by
- Farallon Capital Management closed was 1.3%
- Valueact Capital - Valueact Holdings closed was 0.68%
- Davidson Kempner Capital Management closed was 0.26%
- First Pacific Advisors closed was 0.01%
- Lee Ainslie - Maverick Capital closed was <0.01%
-
CRM Salesforce Inc. 5 managers was avg 0.43% of book · Ako Capital, George Soros - Soros Fund Management and 3 more
Closed by
- Ako Capital closed was 1.3%
- George Soros - Soros Fund Management closed was 0.74%
- Corvex Management closed was 0.11%
- Cathie Wood - Ark Investment Management closed was <0.01%
- Polen Capital Management closed was <0.01%
-
ASML Asml Hldg NV 4 managers was avg 4.5% of book · Rule One Partners, Ning Jin - Avantyr Capital Partners and 2 more
Closed by
- Rule One Partners closed was 9.3%
- Ning Jin - Avantyr Capital Partners closed was 8.5%
- Dan Sundheim - D1 Capital Partners closed was 0.08%
- Situational Awareness closed was 0.04%
-
COHR Coherent Corp. 4 managers was avg 4.0% of book · Estuary Capital Management, Sachem Head Capital Management and 2 more
Closed by
- Estuary Capital Management closed was 6.2%
- Sachem Head Capital Management closed was 5.5%
- Ram Parameswaran - Octahedron Capital Management closed was 3.9%
- Stanley Druckenmiller - Duquesne Family Office closed was 0.29%
Where the money went
Net bought by sector, with price moves taken out. Pick a sector to see its names.
- Communication Services 8.9% weight · −0.1 pts +$15.7B 35 bought · 46 sold
- Consumer Discretionary 15.4% weight · −0.4 pts +$8.2B 50 bought · 42 sold
- Real Estate 2.2% weight · −0.8 pts +$2.4B 14 bought · 15 sold
- Materials 3.7% weight · +0.1 pts +$1.9B 19 bought · 20 sold
- Consumer Staples 3.2% weight · +0.1 pts +$1.6B 21 bought · 14 sold
- Industrials 11.0% weight · +0.3 pts −$962M 36 bought · 46 sold
- Utilities 1.3% weight · −0.2 pts −$1.8B 9 bought · 11 sold
- Health Care 13.0% weight · +0.7 pts −$2.5B 38 bought · 39 sold
- Energy 3.9% weight · −0.8 pts −$3.1B 9 bought · 22 sold
- Financials 17.0% weight · +0.4 pts −$3.4B 44 bought · 48 sold
- Information Technology 20.2% weight · +0.8 pts −$5B 36 bought · 62 sold
Real Estate lost weight (−0.8 pts) even though managers bought $2.4B of it: weight follows price, not buying. Names without a sector (funds, foreign listings, private shares): −$1.3B.
Who moved the most
The biggest new positions, measured against each manager’s own book, and the managers that traded the most of theirs.
Biggest new bets
- King Street Capital Management opened USHY · Ishares Tr 19.5% of book
- Marc Stad - Dragoneer Investment Group opened AMD · Advanced Micro Devices Inc. 19.3% of book
- Alex Roepers - Atlantic Investment Management opened ASH · Ashland Inc. 17.5% of book
- David Witzke - Avidity Partners Management opened CGON · Cg Oncology Inc. 15.9% of book
- Bill Ackman - Pershing Square opened UBER · Uber Technologies Inc. 12.7% of book
- Nehal Chopra - Ratan Capital Management opened SIMO · Silicon Motion Technology Co. 12.7% of book
Most active managers
- Bill Ackman - Pershing Square 12 opened · 0 closed · +$18.7B net 3280% of book traded
- Spencer Waxman - Shannon River Fund Management 18 opened · 12 closed · +$185M net 177% of book traded
- Estuary Capital Management 11 opened · 12 closed · −$291M net 150% of book traded
- Dan Loeb - Third Point 12 opened · 8 closed · +$2.2B net 136% of book traded
- Marc Stad - Dragoneer Investment Group 2 opened · 10 closed · −$2B net 123% of book traded
- Nehal Chopra - Ratan Capital Management 12 opened · 8 closed · −$58M net 122% of book traded
What they hold
Most owned counts managers, with the change since last quarter. Largest is the share of the combined book, each manager counting once. Highest conviction is the average position among holders, three or more.
Most owned
- 1 GOOGL / GOOG Alphabet 74 managers +1
- 2 AMZN Amazon Com Inc. 62 managers +2
- 3 MSFT Microsoft Corp. 57 managers −1
- 4 META Meta Platforms Inc. 53 managers +5
- 5 TSM Taiwan Semiconductor Manufac 44 managers −1
- 6 V Visa Inc. 39 managers no change
- 7 NVDA Nvidia Corporation 36 managers −9
- 8 BRK.B / BRK.A Berkshire Hathaway 35 managers no change
- 9 MA Mastercard Incorporated 30 managers no change
- 10 AAPL Apple Inc. 29 managers no change
Largest
- 1 GOOGL / GOOG Alphabet 3.8% held by 74
- 2 AMZN Amazon Com Inc. 2.9% held by 62
- 3 BRK.B / BRK.A Berkshire Hathaway 2.5% held by 35
- 4 SPCX Space Exploration Techn Corp. 2.1% held by 18
- 5 MSFT Microsoft Corp. 1.8% held by 57
- 6 TSM Taiwan Semiconductor Manufac 1.5% held by 44
- 7 META Meta Platforms Inc. 1.4% held by 53
- 8 V Visa Inc. 1.3% held by 39
- 9 CVNA Carvana Co. Cl A 1.3% held by 16
- 10 NVDA Nvidia Corporation 1.00% held by 36
Highest conviction
- 1 SGRY Surgery Partners Inc. avg 18.2% held by 3
- 2 SPCX Space Exploration Techn Corp. avg 15.9% held by 18
- 3 HCC Warrior Met Coal Inc. avg 15.8% held by 3
- 4 GXO Gxo Logistics Incorporated avg 11.7% held by 3
- 5 CVNA Carvana Co. Cl A avg 10.5% held by 16
- 6 BRK.B / BRK.A Berkshire Hathaway avg 9.5% held by 35
- 7 PDD Pdd Holdings Inc. avg 9.1% held by 5
- 8 MRCY Mercury Sys Inc. avg 8.5% held by 3
- 9 VFC Vf Corp. avg 8.3% held by 3
- 10 GIL Gildan Activewear Inc. avg 8.1% held by 3
Did the combined book beat SPY?
Each quarter’s combined book held to the next quarter-end, at the 13Fs’ own prices. Price only, no dividends, and today’s managers throughout. Nobody could have copied it: 13Fs arrive about 45 days after the quarter ends.
Combined book, 8 quarters
+44.2%
SPY
+37.2%
Difference
+6.9 pts
2024 Q2, the start
+0.0% Combined book
+0.0% SPY
2024 Q3, since 2024 Q2
+7.5% Combined book
+5.4% SPY
That quarter: book +7.5%, SPY +5.4%
2024 Q4, since 2024 Q2
+10.2% Combined book
+7.7% SPY
That quarter: book +2.6%, SPY +2.1%
2025 Q1, since 2024 Q2
+6.0% Combined book
+2.8% SPY
That quarter: book −3.8%, SPY −4.6%
2025 Q2, since 2024 Q2
+18.3% Combined book
+13.5% SPY
That quarter: book +11.6%, SPY +10.5%
2025 Q3, since 2024 Q2
+29.0% Combined book
+22.4% SPY
That quarter: book +9.1%, SPY +7.8%
2025 Q4, since 2024 Q2
+31.8% Combined book
+25.3% SPY
That quarter: book +2.1%, SPY +2.4%
2026 Q1, since 2024 Q2
+25.9% Combined book
+19.5% SPY
That quarter: book −4.4%, SPY −4.6%
2026 Q2, since 2024 Q2
+44.2% Combined book
+37.2% SPY
That quarter: book +14.5%, SPY +14.8%
Quarter by quarter
| Quarter | Each manager once | By dollars | SPY | Book − SPY | Managers |
|---|---|---|---|---|---|
| 2026 Q2 | +14.5% | +11.5% | +14.8% | −0.4 pts | 133 |
| 2026 Q1 | −4.4% | −4.2% | −4.6% | +0.2 pts | 136 |
| 2025 Q4 | +2.1% | +2.6% | +2.4% | −0.2 pts | 136 |
| 2025 Q3 | +9.1% | +6.3% | +7.8% | +1.2 pts | 136 |
| 2025 Q2 | +11.6% | +8.0% | +10.5% | +1.1 pts | 136 |
| 2025 Q1 | −3.8% | −2.0% | −4.6% | +0.7 pts | 136 |
| 2024 Q4 | +2.6% | +1.1% | +2.1% | +0.4 pts | 134 |
| 2024 Q3 | +7.5% | +6.9% | +5.4% | +2.1 pts | 133 |
All 2,499 names
Download CSVShowing 300 of 441 matching names. The CSV has every name.
| Ticker | Company | Sector | Held by | Weight | Net bought | Bought / sold | Opened / closed |
|---|---|---|---|---|---|---|---|
| UNH | Unitedhealth Group, Inc. | Health Care | 27 +1 | 0.25% | −$912M | 7 / 11 | 3 / 2 |
| TMO | Thermo Fisher Scientific, Inc. | Health Care | 21 +3 | 0.28% | +$1.7B | 13 / 4 | 4 / 1 |
| DHR | Danaher Corp. Del | Health Care | 20 +3 | 0.29% | +$390M | 9 / 2 | 4 / 1 |
| JNJ | Johnson & Johnson | Health Care | 18 | 0.12% | −$28M | 3 / 6 | 1 / 1 |
| ELV | Elevance Health Inc. Formerly | Health Care | 16 +1 | 0.30% | −$194M | 4 / 5 | 3 / 2 |
| LLY | Eli Lilly & Co. | Health Care | 14 +2 | 0.14% | −$167M | 4 / 2 | 2 / 0 |
| ABT | Abbott Laboratories | Health Care | 14 +1 | 0.11% | −$122M | 4 / 5 | 2 / 1 |
| MRK | Merck & Co. Inc. | Health Care | 14 | 0.05% | −$46M | 1 / 3 | 0 / 0 |
| CVS | Cvs Health Corp. | Health Care | 13 −2 | 0.32% | −$432M | 2 / 8 | 1 / 3 |
| PFE | Pfizer Inc. | Health Care | 12 | 0.09% | +$2M | 4 / 4 | 1 / 1 |
| ABBV | Abbvie Inc. | Health Care | 12 | 0.04% | +$24M | 1 / 5 | 1 / 1 |
| NTRA | Natera Inc. | Health Care | 11 +2 | 0.20% | −$54M | 6 / 3 | 3 / 1 |
| CI | The Cigna Group | Health Care | 11 | 0.13% | +$106M | 2 / 1 | 0 / 0 |
| MDT | Medtronic PLC | Health Care | 11 | 0.09% | +$310M | 4 / 3 | 1 / 1 |
| ICLR | Icon Pub Ltd Co. | Health Care | 9 −3 | 0.24% | −$244M | 4 / 7 | 1 / 4 |
| GEHC | Ge Healthcare Technologies, Inc. | Health Care | 9 −2 | 0.09% | +$633M | 5 / 5 | 1 / 3 |
| BMY | Bristol-Myers Squibb Co. | Health Care | 9 | 0.05% | −$270M | 2 / 2 | 0 / 0 |
| BSX | Boston Scientific Corp. | Health Care | 9 +1 | 0.04% | +$222M | 6 / 3 | 3 / 2 |
| MDLN | Medline Inc. | Health Care | 8 −2 | 0.24% | +$512M | 6 / 4 | 0 / 2 |
| BDX | Becton Dickinson & Co. | Health Care | 8 | 0.18% | +$1.1B | 6 / 2 | 2 / 2 |
| AZN | Astrazeneca PLC | Health Care | 8 +1 | 0.16% | +$443M | 3 / 2 | 1 / 0 |
| BAX | Baxter Intl Inc. | Health Care | 8 | 0.11% | +$59M | 2 / 1 | 0 / 0 |
| WST | West Pharmaceutical Svsc Inc. | Health Care | 8 −4 | 0.10% | −$173M | 0 / 8 | 0 / 4 |
| WAT | Waters Corp. | Health Care | 8 | 0.09% | −$621M | 1 / 4 | 0 / 0 |
| TEVA | Teva Pharmaceutical Inds Ltd | Health Care | 8 | 0.08% | −$127M | 1 / 3 | 0 / 0 |
| IDXX | Idexx Labs Inc. | Health Care | 8 +1 | 0.08% | −$81M | 3 / 3 | 1 / 0 |
| TECH | Bio-Techne Corp. | Health Care | 8 +1 | 0.07% | −$531M | 1 / 5 | 1 / 0 |
| ZBH | Zimmer Biomet Holdings, Inc. | Health Care | 8 | 0.07% | +$7M | 1 / 2 | 0 / 0 |
| NVS | Novartis AG | Health Care | 8 +2 | 0.02% | −$901M | 3 / 2 | 2 / 0 |
| IQV | Iqvia Hldgs Inc. | Health Care | 7 +1 | 0.08% | +$64M | 3 / 1 | 2 / 1 |
| HCA | Hca Healthcare Inc. | Health Care | 7 −1 | 0.07% | −$458M | 1 / 1 | 0 / 1 |
| GSK | Gsk PLC | Health Care | 7 | 0.05% | −$549M | 1 / 3 | 0 / 0 |
| ISRG | Intuitive Surgical Inc. | Health Care | 7 −1 | 0.05% | +$125M | 2 / 5 | 1 / 2 |
| ZTS | Zoetis Inc. | Health Care | 7 +2 | 0.05% | −$509M | 5 / 3 | 4 / 2 |
| AMGN | Amgen Inc. | Health Care | 7 | 0.05% | +$3M | 1 / 0 | 0 / 0 |
| VEEV | Veeva Sys Inc. | Health Care | 7 +4 | 0.05% | +$147M | 4 / 1 | 4 / 0 |
| NVO | Novo Nordisk A/S | Health Care | 7 −1 | 0.03% | +$142M | 3 / 2 | 0 / 1 |
| CAH | Cardinal Health Inc. | Health Care | 7 | 0.01% | −$49M | 3 / 1 | 1 / 1 |
| SOLV | Solventum Corporation | Health Care | 6 | 0.13% | −$3M | 0 / 1 | 0 / 0 |
| SYK | Stryker Corporation | Health Care | 6 −1 | 0.09% | −$151M | 1 / 4 | 0 / 1 |
| REGN | Regeneron Pharmaceuticals, Inc. | Health Care | 6 | 0.08% | +$257M | 3 / 1 | 0 / 0 |
| BIIB | Biogen Inc. | Health Care | 6 | 0.06% | −$19M | 1 / 3 | 1 / 1 |
| SNY | Sanofi SA | Health Care | 6 | 0.05% | −$70M | 2 / 2 | 0 / 0 |
| ROIV | Roivant Sciences Ltd | Health Care | 6 +1 | 0.04% | +$193M | 3 / 1 | 1 / 0 |
| GILD | Gilead Sciences, Inc. | Health Care | 6 | 0.02% | −$75M | 0 / 1 | 0 / 0 |
| RVMD | Revolution Medicines Inc. | Health Care | 5 −1 | 0.26% | −$1M | 2 / 2 | 0 / 1 |
| ILMN | Illumina Inc. | Health Care | 5 −1 | 0.15% | −$278M | 0 / 4 | 0 / 1 |
| COO | Cooper Cos Inc. | Health Care | 5 +2 | 0.13% | +$72M | 2 / 2 | 2 / 0 |
| THC | Tenet Healthcare Corp. | Health Care | 5 −1 | 0.09% | −$314M | 4 / 2 | 1 / 2 |
| HUM | Humana, Inc. | Health Care | 5 −1 | 0.07% | −$689M | 1 / 5 | 1 / 2 |
| CNC | Centene Corp. Del | Health Care | 5 | 0.06% | −$350M | 1 / 3 | 0 / 0 |
| AVTR | Avantor, Inc. | Health Care | 5 −1 | 0.06% | +$36M | 2 / 1 | 0 / 1 |
| NVST | Envista Holdings Corporation | Health Care | 5 −1 | 0.04% | −$51M | 1 / 4 | 0 / 1 |
| BKD | Brookdale Sr Living Inc. | Health Care | 5 | 0.04% | +$22M | 5 / 0 | 0 / 0 |
| PTGX | Protagonist Therapeutics Inc. | Health Care | 5 | 0.04% | +$6M | 2 / 1 | 0 / 0 |
| RGEN | Repligen Corp. | Health Care | 5 +1 | 0.04% | +$103M | 4 / 0 | 1 / 0 |
| BLCO | Bausch Plus Lomb Corp. | Health Care | 5 +1 | 0.02% | +$18M | 2 / 0 | 1 / 0 |
| BNTX | Biontech Se | Health Care | 5 | 0.02% | +$582K | 0 / 0 | 0 / 0 |
| DGX | Quest Diagnostics Inc. | Health Care | 5 −1 | 0.01% | −$13M | 1 / 1 | 0 / 1 |
| RPRX | Royalty Pharma PLC | Health Care | 4 −1 | 0.15% | −$22M | 1 / 2 | 0 / 1 |
| IONS | Ionis Pharmaceuticals Inc. | Health Care | 4 −1 | 0.10% | −$2M | 0 / 2 | 0 / 1 |
| BMRN | Biomarin Pharmaceutical, Inc. | Health Care | 4 | 0.10% | +$48M | 1 / 0 | 0 / 0 |
| XRAY | Dentsply Sirona Inc. | Health Care | 4 | 0.10% | −$118M | 2 / 2 | 0 / 0 |
| VTRS | Viatris Inc. | Health Care | 4 −1 | 0.09% | −$20M | 2 / 1 | 0 / 1 |
| ACHC | Acadia Healthcare Company In | Health Care | 4 −2 | 0.09% | −$110M | 1 / 4 | 0 / 2 |
| MEDP | Medpace Holdings Inc. | Health Care | 4 | 0.06% | −$39M | 0 / 2 | 0 / 0 |
| A | Agilent Technologies Inc. | Health Care | 4 +1 | 0.05% | −$86M | 1 / 1 | 1 / 0 |
| BBIO | Bridgebio Pharma Inc. | Health Care | 4 | 0.04% | −$42M | 1 / 2 | 0 / 0 |
| CRL | Charles Riv Labs Intl Inc. | Health Care | 4 −1 | 0.03% | +$31M | 0 / 2 | 0 / 1 |
| BEAM | Beam Therapeutics Inc. | Health Care | 4 +1 | 0.03% | −$56M | 1 / 1 | 1 / 0 |
| MTD | Mettler Toledo International | Health Care | 4 +1 | 0.03% | −$643M | 2 / 1 | 2 / 1 |
| EW | Edwards Lifesciences Corp. | Health Care | 4 −1 | 0.03% | −$57M | 2 / 1 | 0 / 1 |
| NAMS | Newamsterdam Pharma Company | Health Care | 4 | 0.03% | +$36M | 2 / 1 | 1 / 1 |
| HSIC | Henry Schein, Inc. | Health Care | 4 −1 | 0.03% | +$446K | 1 / 1 | 0 / 1 |
| VRTX | Vertex Pharmaceuticals | Health Care | 4 | 0.02% | −$962K | 0 / 1 | 0 / 0 |
| AXGN | Axogen Inc. | Health Care | 4 | 0.01% | +$2M | 1 / 1 | 0 / 0 |
| ELAN | Elanco Animal Health, Inc. | Health Care | 4 | <0.01% | −$40M | 0 / 2 | 0 / 0 |
| GH | Guardant Health Inc. | Health Care | 4 | <0.01% | +$48M | 1 / 1 | 0 / 0 |
| BTI | British Amern Tob PLC | Health Care | 4 | <0.01% | +$6M | 1 / 0 | 0 / 0 |
| ABVX | Abivax SA | Health Care | 4 +2 | <0.01% | +$28M | 3 / 1 | 2 / 0 |
| RDNT | Radnet Inc. | Health Care | 4 | <0.01% | +$14M | 2 / 1 | 0 / 0 |
| SGRY | Surgery Partners Inc. | Health Care | 3 | 0.41% | −$86M | 1 / 2 | 1 / 1 |
| JAZZ | Jazz Pharmaceuticals PLC | Health Care | 3 +1 | 0.12% | +$433K | 1 / 0 | 1 / 0 |
| ENTA | Enanta Pharmaceuticals Inc. | Health Care | 3 | 0.12% | −$7M | 0 / 1 | 0 / 0 |
| MCK | Mckesson Corp. | Health Care | 3 −1 | 0.12% | −$408M | 1 / 2 | 0 / 1 |
| EXEL | Exelixis Inc. | Health Care | 3 | 0.08% | +$17M | 0 / 1 | 0 / 0 |
| TFX | Teleflex Incorporated | Health Care | 3 | 0.06% | −$62M | 0 / 3 | 0 / 0 |
| UHS | Universal Hlth Svcs Inc. | Health Care | 3 | 0.04% | +$42M | 1 / 0 | 0 / 0 |
| BIO | Bio Rad Labs Inc. | Health Care | 3 −1 | 0.04% | −$39M | 0 / 1 | 0 / 1 |
| INSM | Insmed Inc. | Health Care | 3 +1 | 0.04% | +$257M | 2 / 1 | 1 / 0 |
| URGN | Urogen Pharma Ltd | Health Care | 3 | 0.04% | +$536K | 1 / 2 | 1 / 1 |
| TWST | Twist Bioscience Corp. | Health Care | 3 −1 | 0.03% | −$130M | 2 / 2 | 0 / 1 |
| BRKR | Bruker Corp. | Health Care | 3 +3 | 0.03% | +$244M | 3 / 0 | 3 / 0 |
| ALGN | Align Technology Inc. | Health Care | 3 | 0.03% | −$6M | 0 / 2 | 0 / 0 |
| XENE | Xenon Pharmaceuticals Inc. | Health Care | 3 | 0.02% | $0 | 0 / 0 | 0 / 0 |
| LH | Labcorp Holdings Inc. | Health Care | 3 −1 | 0.02% | −$3M | 0 / 2 | 0 / 1 |
| AKTS | Aktis Oncology Inc. | Health Care | 3 +1 | 0.02% | +$3M | 1 / 0 | 1 / 0 |
| BFLY | Butterfly Network Inc. | Health Care | 3 | 0.02% | −$571K | 1 / 0 | 0 / 0 |
| IMVT | Immunovant Inc. | Health Care | 3 | 0.02% | +$164M | 1 / 0 | 0 / 0 |
| DXCM | Dexcom Inc. | Health Care | 3 −1 | 0.02% | +$265K | 0 / 1 | 0 / 1 |
| ADPT | Adaptive Biotechnologies Cor | Health Care | 3 −1 | 0.02% | −$585K | 0 / 2 | 0 / 1 |
| ALKS | Alkermes PLC | Health Care | 3 −2 | 0.01% | −$7M | 1 / 3 | 0 / 2 |
| MANE | Veradermics Inc. | Health Care | 3 +1 | 0.01% | +$102M | 2 / 1 | 1 / 0 |
| EDIT | Editas Medicine Inc. | Health Care | 3 +1 | <0.01% | +$7M | 2 / 0 | 1 / 0 |
| INBX | Inhibrx Biosciences Inc. | Health Care | 3 +2 | <0.01% | −$26M | 2 / 1 | 2 / 0 |
| EHC | Encompass Health Corp. | Health Care | 3 −1 | <0.01% | +$12M | 1 / 2 | 0 / 1 |
| Inmode | Inmode Ltd | Health Care | 3 | <0.01% | −$850K | 0 / 1 | 0 / 0 |
| SRTA | Strata Critical Medical Inc. | Health Care | 3 | <0.01% | −$25M | 0 / 1 | 0 / 0 |
| NUVB | Nuvation Bio Inc. | Health Care | 3 −1 | <0.01% | −$165K | 0 / 1 | 0 / 1 |
| TRVI | Trevi Therapeutics Inc. | Health Care | 3 | <0.01% | −$32M | 0 / 2 | 0 / 0 |
| AXSM | Axsome Therapeutics | Health Care | 3 | <0.01% | +$369K | 2 / 1 | 1 / 1 |
| CDNA | Caredx Inc. | Health Care | 3 | <0.01% | −$47M | 0 / 2 | 0 / 0 |
| KLRA | Kailera Therapeutics Inc. IPO or spin-off | Health Care | 3 +3 | <0.01% | +$26M | 3 / 0 | 3 / 0 |
| Compugen | Compugen Ltd | Health Care | 3 | <0.01% | −$755K | 0 / 2 | 0 / 0 |
| DNTH | Dianthus Therapeutics Inc. | Health Care | 2 −1 | 0.25% | −$81M | 1 / 1 | 0 / 1 |
| MDGL | Madrigal Pharmaceuticals Inc. | Health Care | 2 −1 | 0.21% | −$30M | 0 / 3 | 0 / 1 |
| NVAX | Novavax Inc. | Health Care | 2 −1 | 0.19% | −$7M | 0 / 2 | 0 / 1 |
| LQDA | Liquidia Corporation | Health Care | 2 | 0.16% | −$31M | 0 / 1 | 0 / 0 |
| CGON | Cg Oncology Inc. | Health Care | 2 | 0.12% | +$46M | 1 / 2 | 1 / 1 |
| ALC | Alcon AG | Health Care | 2 −2 | 0.11% | −$232M | 2 / 2 | 0 / 2 |
| ORKA | Oruka Therapeutics Inc. | Health Care | 2 | 0.09% | −$111M | 0 / 1 | 0 / 0 |
| WGS | Genedx Holdings Corp. | Health Care | 2 −2 | 0.08% | +$121M | 2 / 2 | 0 / 2 |
| ETON | Eton Pharmaceuticals Inc. | Health Care | 2 | 0.07% | +$552K | 1 / 0 | 0 / 0 |
| HROW | Harrow Inc. | Health Care | 2 +1 | 0.07% | +$16M | 1 / 1 | 1 / 0 |
| SHC | Sotera Health Co. | Health Care | 2 | 0.06% | +$106M | 2 / 0 | 0 / 0 |
| JBIO | Jade Biosciences Inc. | Health Care | 2 | 0.05% | +$386K | 1 / 1 | 0 / 0 |
| SUPN | Supernus Pharmaceuticals Inc. | Health Care | 2 −1 | 0.05% | −$186K | 0 / 1 | 0 / 1 |
| CMPS | Compass Pathways PLC | Health Care | 2 | 0.04% | −$4M | 0 / 1 | 0 / 0 |
| APGE | Apogee Therapeutics Inc. | Health Care | 2 | 0.04% | +$73M | 1 / 1 | 1 / 1 |
| RARE | Ultragenyx Pharmaceutical In | Health Care | 2 | 0.04% | −$467K | 0 / 1 | 0 / 0 |
| OSCR | Oscar Health Inc. | Health Care | 2 −1 | 0.04% | −$10M | 1 / 2 | 1 / 2 |
| ELVN | Enliven Therapeutics Inc. | Health Care | 2 +1 | 0.03% | +$8M | 2 / 0 | 1 / 0 |
| EWTX | Edgewise Therapeutics Inc. | Health Care | 2 | 0.03% | +$5M | 1 / 0 | 0 / 0 |
| CRSP | Crispr Therapeutics AG | Health Care | 2 | 0.03% | −$101M | 0 / 1 | 0 / 0 |
| INCY | Incyte Corp. | Health Care | 2 | 0.03% | −$35M | 0 / 0 | 0 / 0 |
| ATRC | Atricure Inc. | Health Care | 2 | 0.02% | +$993K | 1 / 0 | 0 / 0 |
| MOH | Molina Healthcare Inc. | Health Care | 2 −2 | 0.02% | −$160M | 0 / 2 | 0 / 2 |
| STOK | Stoke Therapeutics Inc. | Health Care | 2 −1 | 0.02% | −$294K | 0 / 1 | 0 / 1 |
| LNTH | Lantheus Hldgs Inc. | Health Care | 2 +1 | 0.02% | +$888K | 1 / 0 | 1 / 0 |
| CYTK | Cytokinetics Inc. | Health Care | 2 | 0.02% | −$5M | 0 / 2 | 0 / 0 |
| VNDA | Vanda Pharmaceuticals Inc. | Health Care | 2 | 0.02% | −$7K | 0 / 0 | 0 / 0 |
| RMD | Resmed Inc. | Health Care | 2 | 0.02% | +$31M | 1 / 0 | 0 / 0 |
| ASND | Ascendis Pharma A/S | Health Care | 2 −1 | 0.02% | +$6M | 1 / 2 | 0 / 1 |
| DVA | Davita Inc. | Health Care | 2 | 0.02% | −$254M | 1 / 0 | 0 / 0 |
| PODD | Insulet Corp. | Health Care | 2 −1 | 0.02% | +$8M | 2 / 1 | 0 / 1 |
| NBIX | Neurocrine Biosciences, Inc. | Health Care | 2 | 0.02% | +$19M | 0 / 1 | 0 / 0 |
| PBH | Prestige Consmr Healthcare I | Health Care | 2 +1 | 0.02% | +$31M | 2 / 0 | 1 / 0 |
| SNDX | Syndax Pharmaceuticals Inc. | Health Care | 2 −1 | 0.01% | +$3M | 2 / 1 | 0 / 1 |
| MOBI | Mobia Med Inc. IPO or spin-off | Health Care | 2 +2 | 0.01% | +$26M | 2 / 0 | 2 / 0 |
| TNGX | Tango Therapeutics Inc. | Health Care | 2 +1 | 0.01% | +$100M | 2 / 0 | 1 / 0 |
| GLUE | Monte Rosa Therapeutics Inc. | Health Care | 2 +2 | 0.01% | +$25M | 2 / 0 | 2 / 0 |
| RYTM | Rhythm Pharmaceuticals Inc. | Health Care | 2 +1 | 0.01% | +$23M | 1 / 0 | 1 / 0 |
| EMBC | Embecta Corporation | Health Care | 2 −1 | 0.01% | +$3M | 2 / 1 | 0 / 1 |
| KPTI | Karyopharm Therapeutics Inc. | Health Care | 2 −1 | 0.01% | +$4M | 1 / 1 | 0 / 1 |
| GKOS | Glaukos Corp. | Health Care | 2 +1 | 0.01% | +$39M | 2 / 1 | 2 / 1 |
| MBX | Mbx Biosciences Inc. | Health Care | 2 | 0.01% | −$9M | 0 / 1 | 0 / 0 |
| REPL | Replimune Group Inc. | Health Care | 2 +1 | 0.01% | +$15M | 1 / 0 | 1 / 0 |
| GPCR | Structure Therapeutics Inc. | Health Care | 2 | <0.01% | +$3M | 1 / 0 | 0 / 0 |
| GRAL | Grail Inc. | Health Care | 2 | <0.01% | +$62M | 1 / 0 | 0 / 0 |
| ANNX | Annexon Inc. | Health Care | 2 −1 | <0.01% | −$3M | 1 / 2 | 0 / 1 |
| Catalyst Pharmaceutic… | Catalyst Pharmaceuticals Inc. | Health Care | 2 | <0.01% | −$16M | 1 / 1 | 1 / 1 |
| QTTB | Q32 Bio Inc. | Health Care | 2 +1 | <0.01% | −$4M | 1 / 1 | 1 / 0 |
| LKFT | Lakefront Biotherapeutics NV | Health Care | 2 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| FMS | Fresenius Medical Care AG | Health Care | 2 | <0.01% | −$1M | 0 / 0 | 0 / 0 |
| CAI | Caris Life Sciences Inc. | Health Care | 2 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| VCYT | Veracyte Inc. | Health Care | 2 −1 | <0.01% | −$45M | 0 / 2 | 0 / 1 |
| PHG | Koninklijke Philips NV | Health Care | 2 | <0.01% | +$17M | 2 / 0 | 0 / 0 |
| BTSG | Brightspring Health Svcs Inc. | Health Care | 2 +1 | <0.01% | +$121M | 2 / 0 | 1 / 0 |
| VSTM | Verastem Inc. | Health Care | 2 +1 | <0.01% | +$8M | 2 / 0 | 1 / 0 |
| BLTE | Belite Bio Inc. | Health Care | 2 | <0.01% | +$61M | 1 / 1 | 1 / 1 |
| ALLO | Allogene Therapeutics Inc. | Health Care | 2 | <0.01% | +$1M | 1 / 0 | 0 / 0 |
| OCUL | Ocular Therapeutix Inc. | Health Care | 2 −1 | <0.01% | −$1M | 0 / 2 | 0 / 1 |
| KYMR | Kymera Therapeutics Inc. | Health Care | 2 +1 | <0.01% | +$3M | 1 / 0 | 1 / 0 |
| SDGR | Schrodinger Inc. | Health Care | 2 −1 | <0.01% | +$1M | 0 / 1 | 0 / 1 |
| ADMA | Adma Biologics Inc. | Health Care | 2 | <0.01% | +$10M | 1 / 0 | 0 / 0 |
| WVE | Wave Life Sciences Ltd | Health Care | 2 | <0.01% | +$678K | 0 / 0 | 0 / 0 |
| BBOT | Bridgebio Oncology Therapeut | Health Care | 2 | <0.01% | +$5M | 1 / 0 | 0 / 0 |
| PHAT | Phathom Pharmaceuticals Inc. | Health Care | 2 +1 | <0.01% | +$1M | 1 / 1 | 1 / 0 |
| MAZE | Maze Therapeutics Inc. | Health Care | 2 | <0.01% | +$23M | 2 / 0 | 0 / 0 |
| BHVN | Biohaven Ltd | Health Care | 2 +1 | <0.01% | −$9M | 1 / 1 | 1 / 0 |
| SRRK | Scholar Rock Hldg Corp. | Health Care | 2 | <0.01% | +$11M | 1 / 1 | 1 / 1 |
| RCKT | Rocket Pharmaceuticals Inc. | Health Care | 2 | <0.01% | +$1M | 1 / 0 | 0 / 0 |
| SPRY | Ars Pharmaceuticals Inc. | Health Care | 2 −1 | <0.01% | −$10M | 1 / 1 | 0 / 1 |
| HALO | Halozyme Therapeutics | Health Care | 2 | <0.01% | +$41K | 0 / 0 | 0 / 0 |
| DFTX | Definium Therapeutics Inc. | Health Care | 2 +2 | <0.01% | +$41M | 2 / 0 | 2 / 0 |
| PROF | Profound Med Corp. | Health Care | 2 | <0.01% | +$764K | 1 / 0 | 0 / 0 |
| ALNY | Alnylam Pharmaceuticals, Inc. | Health Care | 2 | <0.01% | +$8M | 0 / 0 | 0 / 0 |
| MRNA | Moderna Inc. | Health Care | 2 +2 | <0.01% | +$140M | 2 / 0 | 2 / 0 |
| Scynexis | Scynexis Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$2M | 2 / 0 | 2 / 0 |
| COR | Cencora Inc. | Health Care | 2 | <0.01% | +$17M | 1 / 1 | 1 / 1 |
| PRME | Prime Medicine Inc. | Health Care | 2 | <0.01% | +$8M | 1 / 0 | 0 / 0 |
| ARTV | Artiva Biotherapeutics Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$26M | 2 / 0 | 2 / 0 |
| TALK | Talkspace Inc. | Health Care | 2 | <0.01% | −$322K | 0 / 1 | 0 / 0 |
| OSUR | Orasure Technologies Inc. | Health Care | 2 +1 | <0.01% | +$5M | 1 / 1 | 1 / 0 |
| COAG | Hemab Therapeutics Hldgs Inc. IPO or spin-off | Health Care | 2 +2 | <0.01% | +$3M | 2 / 0 | 2 / 0 |
| BLLN | Billiontoone Inc. | Health Care | 2 | <0.01% | +$370K | 1 / 1 | 1 / 1 |
| MRVI | Maravai Lifesciences Hldgs I | Health Care | 2 | <0.01% | +$7M | 1 / 0 | 0 / 0 |
| AMN | Amn Healthcare Svcs Inc. | Health Care | 2 +1 | <0.01% | +$7M | 2 / 0 | 1 / 0 |
| TSHA | Taysha Gene Therapies Inc. | Health Care | 2 +1 | <0.01% | +$16M | 2 / 0 | 1 / 0 |
| ADCT | Adc Therapeutics SA | Health Care | 2 +1 | <0.01% | +$754K | 2 / 0 | 1 / 0 |
| WAY | Waystar Hldg Corp. | Health Care | 2 +1 | <0.01% | −$6M | 1 / 1 | 1 / 0 |
| ALVO | Alvotech | Health Care | 2 | <0.01% | +$10M | 1 / 0 | 0 / 0 |
| ESTA | Establishment Labs Hldgs Inc. | Health Care | 2 | <0.01% | −$58M | 0 / 2 | 0 / 0 |
| BCYC | Bicycle Therapeutics PLC | Health Care | 2 | <0.01% | −$3K | 0 / 0 | 0 / 0 |
| UTHR | United Therapeutics Corp. | Health Care | 1 −1 | 0.11% | −$8M | 0 / 2 | 0 / 1 |
| BHC | Bausch Health Cos Inc. | Health Care | 1 | 0.11% | $0 | 0 / 0 | 0 / 0 |
| LFCR | Lifecore Biomedical Inc. | Health Care | 1 | 0.08% | −$2M | 0 / 1 | 0 / 0 |
| ANAB | Anaptysbio | Health Care | 1 +1 | 0.06% | +$12M | 1 / 0 | 1 / 0 |
| IRON | Disc Medicine Inc. | Health Care | 1 | 0.04% | +$32M | 1 / 0 | 0 / 0 |
| STXS | Stereotaxis Inc. | Health Care | 1 | 0.03% | $0 | 0 / 0 | 0 / 0 |
| MGTX | Meiragtx Hldgs PLC | Health Care | 1 | 0.03% | +$19M | 1 / 0 | 0 / 0 |
| NKTR | Nektar Therapeutics | Health Care | 1 −1 | 0.03% | +$10M | 1 / 1 | 0 / 1 |
| DNLI | Denali Therapeutics Inc. | Health Care | 1 −1 | 0.03% | +$9M | 1 / 1 | 0 / 1 |
| ERFSF | Eurofins Scientific | Health Care | 1 | 0.03% | +$78M | 1 / 0 | 0 / 0 |
| PGEN | Precigen Inc. | Health Care | 1 −1 | 0.03% | +$7M | 1 / 1 | 0 / 1 |
| IDYA | Ideaya Biosciences Inc. | Health Care | 1 | 0.03% | +$764K | 0 / 0 | 0 / 0 |
| INDV | Indivior Pharmaceuticals Inc. | Health Care | 1 −1 | 0.03% | +$230M | 1 / 1 | 0 / 1 |
| CATX | Perspective Therapeutics Inc. | Health Care | 1 −1 | 0.03% | −$15M | 0 / 1 | 0 / 1 |
| SLGL | Sol-Gel Technologies Ltd | Health Care | 1 | 0.03% | $0 | 0 / 0 | 0 / 0 |
| RZLT | Rezolute Inc. | Health Care | 1 | 0.02% | $0 | 0 / 0 | 0 / 0 |
| PRVA | Privia Health Group Inc. | Health Care | 1 | 0.02% | −$12M | 0 / 0 | 0 / 0 |
| TGTX | Tg Therapeutics Inc. | Health Care | 1 | 0.02% | $0 | 0 / 0 | 0 / 0 |
| RCUS | Arcus Biosciences Inc. | Health Care | 1 | 0.02% | −$62K | 0 / 0 | 0 / 0 |
| IMMX | Immix Biopharma Inc. IPO or spin-off | Health Care | 1 +1 | 0.02% | +$24M | 1 / 0 | 1 / 0 |
| CBIO | Crescent Biopharma Inc. | Health Care | 1 | 0.02% | +$121K | 0 / 0 | 0 / 0 |
| Bausch Lomb | Bausch Lomb Corp. | Health Care | 1 | 0.02% | −$3M | 0 / 1 | 0 / 0 |
| PVLA | Palvella Therapeutics Inc. Ne | Health Care | 1 | 0.01% | $0 | 0 / 0 | 0 / 0 |
| Immunic | Immunic Inc. IPO or spin-off | Health Care | 1 +1 | 0.01% | +$10M | 1 / 0 | 1 / 0 |
| BCAX | Bicara Therapeutics Inc. | Health Care | 1 | 0.01% | −$4M | 0 / 1 | 0 / 0 |
| FTRE | Fortrea Hldgs Inc. | Health Care | 1 | 0.01% | −$29M | 0 / 1 | 0 / 0 |
| CRNX | Crinetics Pharmaceuticals In | Health Care | 1 | 0.01% | +$24M | 1 / 0 | 0 / 0 |
| HAE | Haemonetics Corp. Mass | Health Care | 1 +1 | 0.01% | +$155M | 1 / 0 | 1 / 0 |
| Senseonics | Senseonics Hldgs Inc. IPO or spin-off | Health Care | 1 +1 | 0.01% | +$9M | 1 / 0 | 1 / 0 |
| ALMS | Alumis Inc. | Health Care | 1 −1 | 0.01% | −$310K | 0 / 1 | 0 / 1 |
| XOMA | Xoma Royalty Corporation | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| OPCH | Option Care Health Inc. | Health Care | 1 −1 | <0.01% | −$98M | 0 / 2 | 0 / 1 |
| MPLT | Maplight Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| LRMR | Larimar Therapeutics Inc. | Health Care | 1 | <0.01% | −$64K | 0 / 0 | 0 / 0 |
| IPSC | Century Therapeutics Inc. | Health Care | 1 | <0.01% | −$83K | 0 / 0 | 0 / 0 |
| CABA | Cabaletta Bio Inc. | Health Care | 1 | <0.01% | +$8M | 1 / 0 | 0 / 0 |
| COLL | Collegium Pharmaceutical Inc. | Health Care | 1 | <0.01% | +$996K | 1 / 0 | 0 / 0 |
| INGN | Inogen Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ARDX | Ardelyx Inc. | Health Care | 1 −1 | <0.01% | +$59K | 1 / 1 | 0 / 1 |
| TNDM | Tandem Diabetes Care Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| AGIO | Agios Pharmaceuticals Inc. | Health Care | 1 | <0.01% | +$9M | 0 / 0 | 0 / 0 |
| RXRX | Recursion Pharmaceuticals Inc. | Health Care | 1 | <0.01% | +$4M | 0 / 0 | 0 / 0 |
| ABSI | Absci Corp. | Health Care | 1 | <0.01% | −$9M | 0 / 1 | 0 / 0 |
| VIR | Vir Biotechnology Inc. | Health Care | 1 −1 | <0.01% | −$1M | 0 / 2 | 0 / 1 |
| LZAGY | Lonza Group Adr | Health Care | 1 | <0.01% | −$76K | 0 / 0 | 0 / 0 |
| PCVX | Vaxcyte Inc. | Health Care | 1 −2 | <0.01% | −$106M | 1 / 2 | 0 / 2 |
| BCRX | Biocryst Pharmaceuticals Inc. | Health Care | 1 −1 | <0.01% | −$540K | 0 / 2 | 0 / 1 |
| PSNL | Personalis Inc. | Health Care | 1 | <0.01% | +$4M | 0 / 0 | 0 / 0 |
| KIDS | Orthopediatrics Corp. | Health Care | 1 | <0.01% | +$2M | 1 / 0 | 0 / 0 |
| DMAC | Diamedica Therapeutics Inc. | Health Care | 1 | <0.01% | +$10M | 1 / 0 | 0 / 0 |
| ZNTL | Zentalis Pharmaceuticals Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| TENX | Tenax Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| KRYS | Krystal Biotech | Health Care | 1 −1 | <0.01% | −$326K | 0 / 1 | 0 / 1 |
| MMSI | Merit Med Sys Inc. | Health Care | 1 −1 | <0.01% | +$18M | 1 / 1 | 0 / 1 |
| RAPP | Rapport Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| RLMD | Relmada Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| PRQR | Proqr Therapeutics NV | Health Care | 1 | <0.01% | −$69K | 0 / 0 | 0 / 0 |
| NGNE | Neurogene Inc. | Health Care | 1 | <0.01% | +$1M | 1 / 0 | 0 / 0 |
| ANL | Adlai Nortye Ltd IPO or spin-off | Health Care | 1 +1 | <0.01% | +$3M | 1 / 0 | 1 / 0 |
| PRCT | Procept Biorobotics Corp. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| AQST | Aquestive Therapeutics Inc. | Health Care | 1 | <0.01% | +$1M | 1 / 0 | 0 / 0 |
| SNN | Smith & Nephew PLC | Health Care | 1 | <0.01% | +$18M | 1 / 0 | 0 / 0 |
| CLDX | Celldex Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| MSLE | Satellos Bioscience Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| AGL | Agilon Health Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$47M | 1 / 0 | 1 / 0 |
| NUVL | Nuvalent Inc. | Health Care | 1 −1 | <0.01% | +$35M | 1 / 2 | 1 / 2 |
| CNTX | Context Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| VKTX | Viking Therapeutics Inc. | Health Care | 1 −1 | <0.01% | −$5M | 0 / 1 | 0 / 1 |
| LYEL | Lyell Immunopharma Inc. | Health Care | 1 | <0.01% | +$4M | 1 / 0 | 0 / 0 |
| IRD | Opus Genetics Inc. | Health Care | 1 −1 | <0.01% | −$4M | 0 / 1 | 0 / 1 |
| EOLS | Evolus Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| NGEN | Nervgen Pharma Corp. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$2M | 1 / 0 | 1 / 0 |
| FDMT | 4D Molecular Therapeutics In | Health Care | 1 | <0.01% | +$3M | 1 / 0 | 0 / 0 |
| SION | Sionna Therapeutics Inc. | Health Care | 1 −1 | <0.01% | −$1M | 0 / 1 | 0 / 1 |
| QURE | Uniqure NV | Health Care | 1 −1 | <0.01% | +$10M | 1 / 1 | 0 / 1 |
| VYGR | Voyager Therapeutics Inc. | Health Care | 1 | <0.01% | +$123K | 0 / 0 | 0 / 0 |
| BDSX | Biodesix Inc. | Health Care | 1 | <0.01% | −$1M | 0 / 1 | 0 / 0 |
| PHVS | Pharvaris N V | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| COYA | Coya Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| ALEC | Alector Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| CERS | Cerus Corp. | Health Care | 1 | <0.01% | −$4M | 0 / 1 | 0 / 0 |
| LXEO | Lexeo Therapeutics Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| RNA | Atrium Therapeutics Inc. | Health Care | 1 | <0.01% | −$3M | 1 / 1 | 1 / 1 |
| CTMX | Cytomx Therapeutics Inc. | Health Care | 1 | <0.01% | +$782K | 1 / 0 | 0 / 0 |
| PBLS | Parabilis Medicines Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$65M | 1 / 0 | 1 / 0 |
| DSGN | Design Therapeutics Inc. IPO or spin-off | Health Care | 1 +1 | <0.01% | +$1M | 1 / 0 | 1 / 0 |
| NRIX | Nurix Therapeutics Inc. | Health Care | 1 | <0.01% | +$2M | 0 / 0 | 0 / 0 |
| SNWV | Sanuwave Health Inc. | Health Care | 1 | <0.01% | −$7M | 0 / 1 | 0 / 0 |
| FATE | Fate Therapeutics Inc. | Health Care | 1 | <0.01% | −$68K | 0 / 0 | 0 / 0 |
| KURA | Kura Oncology Inc. | Health Care | 1 | <0.01% | −$1M | 0 / 1 | 0 / 0 |
| FBIO | Fortress Biotech Inc. | Health Care | 1 | <0.01% | −$465K | 0 / 1 | 0 / 0 |
| OLMA | Olema Pharmaceuticals Inc. | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| MLYS | Mineralys Therapeutics Inc. | Health Care | 1 | <0.01% | +$162K | 1 / 0 | 0 / 0 |
| DERM | Journey Med Corp. | Health Care | 1 | <0.01% | −$4M | 0 / 1 | 0 / 0 |
| GMAB | Genmab A/S | Health Care | 1 | <0.01% | $0 | 0 / 0 | 0 / 0 |
| AVTX | Avalo Therapeutics Inc. | Health Care | 1 | <0.01% | +$29M | 1 / 0 | 0 / 0 |
How the numbers work
Same managers in both quarters
Changes compare only managers with a 13F in both 2026 Q1 and 2026 Q2: 133 this time. Not in 2026 Q2: Robert Olstein - Olstein Capital Management, Kahn Brothers Group, Palo Alto Investors.
Buying versus price
Each holding’s dollar change splits into price (what last quarter’s shares earned by this quarter’s 13F price) and net bought (shares added or cut, times this quarter’s price), using each 13F’s own values. The two add back to the change exactly. Stock splits are adjusted first.
Who counts as a buyer or a seller
A manager bought a stock if it opened a position, or added at least 5% to its shares or a trade worth 0.25% of its book; it sold if it closed the position or cut it by the same amounts. Smaller changes count as holding, and a stock split never counts. A manager was a net buyer for the quarter when its trading added up to at least 0.25% of its book. GOOG and GOOGL count once.
IPOs, spin-offs and mergers
A stock no tracked manager held last quarter (an IPO, a spin-off, a new share class) is not counted as buying, and one nobody holds now (a merger, a delisting) is not counted as selling. Choose them under All names to see them.
Each manager once, or by dollars
By default every manager counts the same, so a list leads with what the most managers did. By dollars ranks by money moved and weighs holdings by size, so the largest books set the order.
Sectors
GICS sectors where the company has one. Funds, foreign listings and private shares have none; their buying is shown on its own, never filed under Other. Sector weights are shares of the names that have a sector.
The combined book against SPY
Each quarter-end’s combined book is held to the next quarter-end at the 13Fs’ own prices: price only, no dividends, and today’s featured managers for every quarter. SPY is the same filings’ price for SPY. It is a record of what the managers held, not something anyone could have copied, because 13Fs arrive about 45 days after the quarter ends.
What a 13F leaves out
Long US-listed stock only: no shorts, cash, bonds or foreign listings, and options are left out here.